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Abstract
In	2014,	the	Italian	Working	Group	for	Infections	in	Critically	Ill	Patient	of	the	Italian	
Association	 of	 Clinical	 Microbiologists	 updated	 the	 recommendations	 for	 the	 di-
agnostic	workflow	 for	bloodstream	 infections	 (BSI).	Two	years	after	publication,	 a	
nationwide	survey	was	conducted	to	assess	the	compliance	with	the	updated	rec-
ommendations	by	clinical	microbiology	 laboratories.	A	total	of	168	microbiologists	
from	168	laboratories,	serving	204	acute	care	hospitals	and	postacute	care	facilities,	
were	 interviewed	 during	 the	 period	 January–October	 2016	 using	 a	 questionnaire	
consisting	of	nineteen	questions	which	assessed	the	 level	of	adherence	to	various	
recommendations.	The	most	critical	 issues	were	as	follows:	(a)	The	number	of	sets	
of	blood	cultures	(BC)	per	1,000	hospitalization	days	was	acceptable	in	only	11%	of	
laboratories;	(b)	the	minority	of	laboratories	(42%)	was	able	to	monitor	whether	BCs	
were	over	or	under-inoculated;	(c)	among	the	laboratories	monitoring	BC	contamina-
tion	(80%),	the	rate	of	contaminated	samples	was	acceptable	in	only	12%	of	cases;(d)	
the	Gram-staining	results	were	reported	within	1	hr	since	BC	positivity	in	less	than	
50%	of	laboratories.	By	contrast,	most	laboratories	received	vials	within	2–4	hr	from	
withdrawal	(65%)	and	incubated	vials	as	soon	as	they	were	received	in	the	laboratory	
(95%).	The	study	revealed	that	compliance	with	the	recommendations	is	still	partial.	
Further	surveys	will	be	needed	to	monitor	the	situation	in	the	future.
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1  | INTRODUC TION
The	recent	technological	advances	in	diagnostic	microbiology	(e.g.	
the	introduction	of	MALDI-TOF-based	methods	and	of	molecular	
biology-based	 syndromic	 panels)	 have	 revolutionized	 the	 work-
flow	of	clinical	microbiology	laboratories	(Brooks,	2013;	Laupland	
&	Valiquette,	 2013;	Opota,	 Corxatto,	 &	 Prod’hom	G.,	 Greub	G.,	
2015).	 Concerning	 blood	 cultures	 (BCs),	 the	 average	 reporting	
time,	can	be	significantly	shortened	providing	clinicians	with	earlier	
information	on	infecting	pathogens	and	their	susceptibility	profile	
that	allow	a	more	rapid	revision	or	confirmation	of	the	empirical	
therapy	(Cohen	et	al.,	2015;	Liesenfeld,	Lehman,	Hunfeld,	&	Kost,	
2014;	Livermore	&	Wain,	2013;	Maurer,	Christner,	Hentschke,	&	
Rohde,	2017).
In	2014,	the	Italian	Working	Group	for	Infections	in	Critically	Ill	
Patient	of	the	Italian	Association	of	Clinical	Microbiologists	(AMCLI)	
revised	and	updated	the	recommendations	for	the	diagnostic	work-
flow	 for	bloodstream	 infections	 (BSIs),	 based	on	 the	most	 recent	
evidences	(GLIPaC,	2014).	The	objectives	of	the	revision	included	
(a)	reviewing	the	workflow	in	consideration	of	recent	technological	
advances,	 (b)	providing	standard	operating	procedures	 (SOPs)	 for	
obtaining/processing	 BCs,	 and	 (c)	 identifying	 indicators	 that,	 as-
sessed	periodically,	could	be	useful	to	monitor	improvement	in	the	
diagnosis	of	BSIs.	The	document	also	underscored	the	importance	
of	certain	fundamental	steps	in	both	the	pre-analytical	and	analyt-
ical	stages	(De	Plato	et	al.,	2019;	GLIPaC,	2014).
Two	years	after	publication,	we	conducted	a	survey	to	evaluate	
the	adherence	to	the	recommendations	by	Italian	clinical	microbiol-
ogy	laboratories.
2  | MATERIAL S AND METHODS
2.1 | Participants and data collection
A	 total	 of	 168	 microbiologists	 (from	 168	 laboratories)	 were	 in-
terviewed.	Altogether	 the	 laboratories	 served	204	hospitals	and	
postacute	care	facilities	(some	laboratories	acted	as	hubs	for	sev-
eral	hospitals).	The	data	were	collected	from	January	to	October	
2016.
2.2 | Survey
Each	participant	received	a	questionnaire	with	19	questions	and	was	
given	assistance	in	answering	from	the	bioMérieux	Italia	Company	
specialists.	 All	 interviewed	were	 bioMérieux	 customers	who	 used	
the	BACT/ALERT	3D	BC	monitoring	system	(bioMérieux).	The	ques-
tionnaires	were	collected	and	processed	anonymously.
Each	 question	 had	 four	 possible	 answers.	 For	 each	 choice,	 a	
score	 (ranging	 from	0	 to	3)	was	assigned	 to	grade	 the	 level	of	ad-
herence	of	the	assessed	behavior	to	the	updated	recommendations	
(Table	A1,	Figure	1).
The	questions	were	as	follows:
	 1.	 How	many	samples	are	taken	for	each	patient,	with	suspected	
bacteraemia,	 on	 the	 same	 day?
	 2.	 At	what	time	distance	from	each	other?
	 3.	 How	many/which	vials	are	inoculated	for	each	sample?
	 4.	 What	is	the	total	volume	of	blood	drawn	for	each	patient	on	the	
same	day?
	 5.	 Are	 repeated	 withdrawals	 performed	 for	 the	 same	 patient	 in	
days	following	the	first?
	 6.	 What	 is	 the	 percentage	 of	 single	 blood	 cultures	 collected	 (in	
adult	patients)?
	 7.	 How	many	blood	 culture	 sets	 are	 collected	 for	 1,000	days	 of	
hospitalization?
	 8.	 What	is	the	percentage	of	blood	cultures	delivered	in	the	labora-
tory	with	a	delay	>2–4	hr	from	the	time	of	sample	collection?
	 9.	 What	is	the	average	time	between	the	delivering	of	BCs	to	the	
laboratory	and	incubating	them	in	the	automatic	systems?
	10.	 What	 is	the	percentage	of	BCs	obtained	only	from	the	central	
venous	device	and	not	accompanied	by	sampling	from	periph-
eral	vein?
	11.	 Can	the	percentage	of	overinoculated	(>10	ml)	or	subinoculated	
(<8	ml)	bottles	be	calculated?	If	so,	report	the	prevalence?
	12.	 What	 incubation	duration	has	been	 set	 on	 the	BC	monitoring	
incubation	system?
	13.	 In	case	of	suspected	endocarditis	or	brucellosis,	is	the	duration	
of	the	incubation	prolonged?
	14.	 Are	positive	bottles	discharged	from	the	 instrument	and	man-
aged	as	soon	as	possible	or	otherwise	processed	in	batches	at	
specific	times	of	the	day?
	15.	 What	is	the	average	communication	time	for	the	Gram-stain	re-
sults	(calculated	from	the	moment	a	BC	turned	positive	until	the	
final	reporting	to	the	clinician)?
	16.	 Do	you	adopt	rapid	identification	methods	and	rapid	antimicro-
bial	susceptibility	testing	directly	on	positive	broth	culture?	If	so,	
which	ones?
	17.	 Does	 your	 laboratory	 information	 system	 record	 and	manage	
(for	statistical	analysis)	the	positivity	time	for	each	bottle?	If	yes,	
reports	the	average.
	18.	 What	is	your	BC	positivity	rate?
	19.	 What	is	your	BC	contamination	rate?	Do	you	produce	cumula-
tive	reports	as	support?
Results	 were	 merged	 to	 calculate	 an	 average	 questionnaire	
score	per	 center	 and	 an	 average	 answer	 score,	 for	 each	question,	
intercenter.
3  | RESULTS
Overall,	 168	 microbiologists	 from	 168	 laboratories	 were	 inter-
viewed.	The	laboratories	served	a	total	of	204	acute	care	hospitals	
and	 postacute	 care	 facilities.	 The	 geographic	 distribution	 of	 the	
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laboratories	was	as	follows:	68	in	northern	Italy,	59	in	central	Italy,	
and	41	in	southern	Italy.
Figure	 1	 shows	 the	 average	 answer	 score	 for	 each	 question.	
Question	no.	16	was	excluded	from	the	evaluation	because	of	the	
low	number	of	responses.	Questions	no.	7,	11,	13,	and	19	yielded	
the	 lowest	 average	 scores.	 Among	 these,	 question	 no.	 7	 (no.	 of	
sets	of	blood	cultures	carried	out	for	1,000	days	of	hospitalization)	
yielded	 the	 lowest	 score.	 Only	 the	 58%	 of	 laboratories	 (98/168)	
F I G U R E  1  Average	of	the	results	
for	each	question	in	all	the	centres	
interviewd.	The	value	at	the	end	of	the	
bars	indicates	the	average	answered	
scored	for	each	question	(score	ranging	
from	0	to	3,	zero	=	no	one	answered)
Concerning question; (question no.) Possible answer
No. of Hospital 
(%)a
Rate	of	blood	cultures	overinoculated	
(>10	ml)	or	subinoculated	(<8	ml);	(11)
>10% 7/70	(10)
5%–10% 19/70	(27)
2%–5% 30/70	(43)
<2% 14/70	(20)
Timeline	in	reporting	Gram-stain	results	
from	positive	blood	cultures;	(15)
>2	hr 20/168	(12)
1−2	hr	during	the	day	and	
>2	hr	in	the	night
25/168	(15)
1−2	hr 24/168	(14)
<1 hr 71/168	(42)
Not	reported 28/168	(17)
Blood	culture	positivity	rate	(%	sets);	(18) <1%	or	>	19% 62/153	(41)
1%–3%	or	17%–19% 18/153	(12)
3%–5%	or	15%–17% 19/153	(12)
5%–15% 54/153	(35)
Contamination	rate	of	blood	cultures	(%	
sets);	(19)b
>10% 51/150	(34)
4%–10% 69/150	(46)
3%–4% 12/150	(8)
≤2%–3% 18/150	(12)
Note: In	the	column	“Possible	answer,”	bold	indicates	the	optimal	answer.
aReferred	to	the	number	of	centers	that	were	able	to	answer.	
bEvidences	that	may	help	to	differentiate	a	contamination	from	a	true	bacteremia	include:	(a)	
identity	of	the	microorganism	(coagulase-negative	staphylococci	[CoNS],	Corynebacterium	species,	
Bacillus	species	other	than	anthracis,	Propionibacterium acnes,	and	Micrococcus	species	are	usually	
considered	contaminants);	(b)	number	of	positive	culture	sets;	(c)	number	of	positive	bottles	within	
a	set;	and	(d)	time	to	positivity.	
TA B L E  1  Performances	of	the	
hospitals	in	monitoring	some	key	
indicators	useful	for	verifying	that	the	
blood	culture	process	is	under	control
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were	able	to	monitor	this	parameter,	and	only	in	11%	(19/168),	the	
parameter	was	 in	 the	expected	range	 (Table	1).	Answers	to	ques-
tion	no.	11	 showed	 that	 a	minority	of	 laboratories	 (42%;	70/168)	
were	able	to	monitor	whether	BCs	were	over	or	under-inoculated,	
and	among	those	able	to	perform	monitoring,	only	a	small	number	
(14/70)	had	acceptable	rates	of	inocula	<2%	(Table	1).	Question	no.	
13,	regarding	the	need	to	extend	the	incubation	time	in	case	of	sus-
pected	brucellosis,	showed	heterogeneous	behaviors,	with	50%	of	
laboratories	 reporting	 an	 extension	 of	 the	 incubation	 time,	while	
the	indication	by	the	literature	is	to	not	extend	the	incubation	time.	
Brucella	spp.,	in	fact,	is	able	to	grow	within	the	traditional	5	days	of	
incubation	 (GLIPaC,	2014;	Habib,	Lancellotti,	&	 Iung,	2016;	Lamy,	
Dargère,	Arendrup,	 Parienti,	 &	 Tattevin,	 2016).	 Concerning	 ques-
tion	 no.	 19,	 89%	 of	 laboratories	 involved	 (150/168)	were	 able	 to	
report	data	on	contamination	rate;	only	12%	(18/150)	were	in	the	
expected	 range	 (2%–3%),	while	 a	 significant	 number	 of	 hospitals	
were	largely	beyond	scale	(Table	1).
Questions	no.	1,	3,	8,	9,	12,	and	14	were	those	which	yielded	an	
average	 answer	 score	 ≥2,	 indicating	 satisfactory	 adherence	 of	 the	
laboratories	to	the	recommendations	 (Figure	1).	 In	particular,	ques-
tion	no.	1	assessed	compliance	with	the	best	practice	statement	that	
strongly	 recommend	 the	collection	of	at	 least	 two	sets	of	BCs	per	
patient	 (Lamy	et	al.,	2016;	Rhodes	et	al.,	2017).	These	results	were	
overall	consistent	with	those	yielded	from	question	no.	3,	about	the	
number	of	vials	inoculated	for	each	sample	(Figure	2).	The	high	scores	
obtained	for	questions	no.	8	and	9	suggest	a	good	adherence	to	rec-
ommendations	 for	 the	pre-analytical	 phase	 in	 the	BC	workflow.	 In	
particular,	question	no.	8	revealed	that	the	majority	(110/168,	65%)	
of	the	laboratories	received	vials	in	an	optimal	time	frame	(between	2	
and	4	hr).	However,	40	laboratories	were	unable	to	evaluate	this	pa-
rameter,	while	the	remaining	18	received	vials	with	a	delay	exceeding	
4	hr	from	the	time	of	collection.	Responses	to	question	no.14	revealed	
that	most	 laboratories	 (161	of	168,	95%)	 incubated	BCs	as	soon	as	
they	were	received	in	the	laboratory.	Finally,	the	answers	to	question	
no.	15	(time	for	Gram-stain	results	reporting)	showed	an	overall	good	
compliance	with	the	recommendation	to	perform	and	communicate	
Gram-stain	results	on	positive	BCs	as	soon	as	possible	(Clerc	et	al.,	
2013;	GLIPaC,	2014;	Thairu,	Nasir,	&	Usman,	2014).	Out	of	the	168	
laboratories,	140	(83%)	always	reported	Gram-stain	results,	28	(17%)	
either	did	not	report	at	all	or	occasionally	(Figure	3).	More	relevant,	
however,	is	the	evaluation	of	the	timing	of	communication	of	the	re-
sults	of	microscopic	observation	(Table	1).	In	particular,	42%	(71/168)	
of	 the	 laboratories	 reported	 the	 result	of	Gram-stain	 from	positive	
BCs	in	timely	manner	(score	3	was	assigned	to	a	reporting	time	≤1	hr)	
and	another	40%	(20	+	25	+	24/168)	reported	the	results	with	a	sig-
nificant	delay	(Table	1).
Answers	 to	question	no.	17	demonstrated	that	 the	majority	of	
the	laboratories	calculated	and	reported	the	time	to	positivity	(TTP)	
for	each	BC	bottle,	with	148/168	(88%)	having	these	data	available.	
This	 question	 included	 an	 assessment	 of	 the	 average	 TTP,	 which	
ranged	from	15–30	hr	for	108	laboratories,	from	0	to	15	hr	for	five	
laboratories,	and	from	30	to	50	hr	for	35	laboratories.
As	for	the	positivity	rate	of	BCs	(question	no.	18),	most	laborato-
ries	(91%;	153/168)	monitored	this	parameter,	but	only	35%	of	them	
were	within	the	expected	positivity	rate	range	(5%–15%)	(Table	1).
4  | DISCUSSION
Blood	cultures	remains	the	gold	standard	for	the	diagnosis	of	BSIs.	
As	Miller	 et	 al.	 stated	 in	 their	 guidelines,	 "the	diagnosis	 of	 blood-
stream	 infections	 is	 one	 of	 the	 most	 critical	 functions	 of	 clinical	
microbiology	 laboratories"	 (Miller	 et	 al.,	 2018).	 Therefore,	 it	 is	 of	
fundamental	 importance	 for	 microbiologists,	 based	 on	 the	 avail-
able	 technological	 and	 human	 resources,	 to	 implement	 a	 diagnos-
tic	workflow	capable	of	returning	useful	results	to	clinicians	in	the	
shortest	possible	timeframe	to	maximize	impact	on	clinical	decisions	
and	 patients	 outcomes	 (Serpa-Pinto	 &	 Cardoso,	 2014;	 Seymour	
et	al.,	2017;	Yealy	et	al.,	2015).	Monitoring	 suitable	 indicators	can	
contribute	 to	 these	purposes	 (Lamy,	 Ferroni,	Henning,	Cattoen,	&	
Laudat,	2018).	Therefore,	 the	 rules	 and	 indicators	 reported	 in	our	
recommendations	should	not	be	perceived	as	a	burden	for	the	labo-
ratory	but	 rather	as	a	guidance	 to	 improve	 the	use	of	BCs	 for	 the	
benefit	of	patients	(GLIPaC,	2014).
F I G U R E  2  Number	of	set	received	for	each	BC,	expressed	in	
percentage	for	each	Hospital.	A	(1)	=	one	set;	B	(2)	=	two	sets;	C	
(3)	=	three	sets;	D	(4)	=	four	sets
F I G U R E  3  Hospital	Adherence	in	Gram-stain	reporting.	“yes”	
means	that	the	microbiologist	always	reported	Gram-stain	results;	
“no”	that	microbiologist	never	reported	results;	“sometimes”	that	
microbiologist	communicated	results	occasionally
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With	the	intention	to	monitor	the	adherence	to	our	document	by	
the	clinical	microbiology	laboratories	and	to	identify	areas	for	improve-
ment,	we	conducted	a	fact-finding	survey	in	our	country.	From	the	data	
collected,	several	critical	issues	were	detected,	showing	that	adherence	
to	 the	 recommendations	 is	 still	 far	 from	satisfactory.	Some	of	 these	
issues	 deserve	 a	 special	 attention.	 First,	 and	probably	 the	most	 im-
portant,	is	the	deviation	from	the	minimum	required	number	of	blood	
cultures	ordered	(the	optimal	is	103–108	per	1,000	hospital/days).	This	
indicator,	although	not	properly	indicative	of	laboratory	performance,	
can	indicate	correct/incorrect	behaviors	of	clinicians	in	ordering	BCs	
(EARSnet,	2012;	Karch	et	al.,	2015).	A	second	critical	 issue	 is	 that	a	
significant	percentage	of	the	laboratories	perform	the	Gram-stain	and	
communicate	the	results	in	times	longer	than	those	recommended.	It	
is	well	demonstrated	from	the	literature,	how	this	delay	may	impact	on	
patient	outcomes	(Clerc	et	al.,	2013;	Thairu	et	al.,	2014).	A	third	critical	
issue	concerns	contamination	rates,	which	deserves	more	awareness	
and	attention.	The	optimal	value	is	<3%,	but	only	10%	of	laboratories	
were	in	this	range.	Reducing	the	number	of	contaminated	BCs	avoids	
useless	 or	 even	 misleading	 reports	 (Bates,	 Goldman,	 &	 Lee,	 1991;	
Dawson,	2014;	Gander,	2009;	Jakko,	Hilt,	&	Bosboomb,	2013;	Snyder	
et	al.,	2012).	This	parameter,	which	reflects	the	quality	of	withdrawal	
practices	in	terms	of	asepsis	conditions	during	the	collection	of	BCs,	is	
also	useful	to	understand	when	and	where	it	is	necessary	to	organize	
training	courses	for	medical	and/or	nursing	staff	on	methods	for	BC	
collection,	storage,	and	transport	standards	(Rupp,	Cavalieri,	Marolf,	&	
Lyden,	2017;	Snyder	et	al.,	2012).	Another	critical	issue	related	with	the	
performance	of	 laboratories	was	 that	very	 few	 laboratories	monitor	
the	volume	of	blood	inoculated	in	BCs.
In	an	era	of	remarkable	technology	innovation	in	clinical	microbi-
ology,	a	drastic	reduction	of	reporting	times	is	possible	(Arena	et	al.,	
2016;	Özenci	&	Rossolini,	2019).	In	this	perspective,	it	is	noteworthy	
that	most	laboratories	were	unable	to	answer	question	no.	16,	which	
had	the	purpose	of	evaluating	the	diffusion	of	rapid	diagnostic	sys-
tems	for	BCs.	Therefore,	it	could	be	useful	to	repeat	this	survey	in	
the	 future,	 focusing	on	this	aspect.	Microbiologists	should	also	be	
encouraged	to	better	apply	the	SOPs	on	BCs	before	the	next	survey,	
to	verify	whether	a	call	for	adherence	to	the	procedures	is	actually	
effective	in	achieving	greater	compliance.
5  | CONCLUSIONS
In	conclusion,	optimal	practices	of	BC	sampling	and	processing	re-
quire	thorough	understanding	of	several	issues.	Quality	control	pro-
grams,	including	software-based	controls	of	pre-	and	postanalytical	
variables,	should	be	strengthened	to	address	the	shortcomings	de-
scribed	 by	 numerous	 authors	 and	 also	 emerged	 in	 our	 study.	We	
hope	that	the	results	of	this	first	survey	could	encourage	microbiolo-
gists	to	improve	adherence	to	BC	guidelines	and	recommendations.
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APPENDIX 
TA B L E  A 1  Scores	assigned	to	each	possible	response	are	
based	on	adherence	of	the	assessed	behavior	to	the	updated	
recommendations
 Score
Question	1:	How	many	samples	are	taken	for	each	
patient	on	the	same	day?
 
Answers  
1	Sample 0
2	Samples 2
3	Samples 3
4	Samples 1
Question	2:	At	what	temporal	distance	from	each	other?  
Answers  
Withdrawals	spaced	from	>60	min	and	after	empirical	
therapy	and	regardless	of	when	antibiotic	therapy	is	
given
0
Withdrawals	spaced	from	30–60	min	and	after	empirical	
therapy	and	regardless	of	when	antibiotic	therapy	is	
given
1
Withdrawals	taken	at	a	distance	≤30–60	min	before	the	
start	of	empirical	therapy	or	in	any	case	before	a	new	
administration
2
Close	sampling	(5–10	min)	before	the	start	of	empirical	
therapy	or	in	any	case	before	a	new	administration
3
Question	3:	How	many/which	vials	are	inoculated	for	
each	sample?
 
Answers  
1	Single	adult-bottle	for	both	adults	and	children 0
1	Single	adult-bottle	and	one	dedicated	bottle	for	
pediatrics
1
2	Bottles	for	adults	and	one	adult	bottle	also	used	for	
pediatric	sampling
2
2	Bottles	for	adults	and	one	bottle	for	children 3
Question	4:	What	is	the	total	volume	of	blood	taken	for	
each	patient	on	the	same	day?
 
Answers  
<5	ml 0
>40	ml	and	<	20	ml 1
30–40	ml 2
20–30	ml 3
Question	5:	Are	repeated	withdrawals	performed	for	the	
same	patient	in	days	following	the	first?
 
Answers  
No,	never 0
Yes,	often/always	even	in	the	absence	of	clinical	data 1
Yes,	but	only	in	the	presence	of	relevant	clinical	data 2
(Continues)
 Score
Yes,	but	only	in	some	cases	as	sepsis	from	S.	aureus,	
to	guide	therapy	in	case	of	candidemia,	endocarditis	
in	case	of	negativity	of	the	first	three	sets	or	in	the	
presence	of	relevant	clinical	data
3
Question	6:	What	is	the	percentage	of	single	blood	
cultures	collected	(in	adult	patients)?
 
Answers  
>10% 0
5%–10% 1
3%–5% 2
0%–3% 3
Question	7:	How	many	blood-culture	sets	are	collected	
for	1,000	days	of	hospitalization?
 
0–50	and	>250 0
220–250 1
50–103	and	188–220 2
Ranging	between	103	and	188 3
Question	8:	What	is	the	percentage	of	blood	cultures	
delivered	in	the	laboratory	with	a	delay	>2–4	hr	from	the	
time	of	the	sample	collection?
 
not	defined  
Question	9:	What	is	the	average	time	between	the	
delivery	of	BCs	in	the	laboratory	and	its	incubation	into	
the	automatic	systems?
 
Answers  
>4	hr 0
3–4	hr 1
2–3	hr 2
<2	hr 3
Question	10:	What	is	the	percentage	of	BCs	taken	only	
by	central	venous	device	and	not	accompanied	by	
peripheral	vein	withdrawal?
 
Answers  
>7% 0
5%–7% 1
About	5% 2
<5% 3
Question	11:	Can	you	calculate	the	percentage	of	over-
inoculated	(>10	ml)	or	sub-inoculated	(<8	ml)	bottles?	If	
so,	what	is	its	prevalence?
 
Answers  
>10% 0
5%–10% 1
2%–5% 2
<2% 3
Question	12:	What	incubation	duration	has	been	set	on	
your	BC	monitoring	incubation	system?
 
<5	and	>7	days 0
TA B L E  A 1   (Continued)
(Continues)
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 Score
7	days 1
6	days 2
5	days 3
Question	13:	In	case	of	suspected	endocarditis	or	
brucellosis,	is	the	duration	of	the	incubation	prolonged?
 
Yes 0
No 3
Question	14:	Are	positive	bottles	downloaded	from	
the	instrument	and	managed	as	soon	as	possible	or	
otherwise	they	are	processed	in	batch	at	specific	times	
of	the	day?
 
Batch	removal	of	positive	bottles 0
Positive-bottles	are	discharged	every	1–2	hr	during	the	
day	and	>2	hr	at	night
1
Positive-bottles	are	removed	every	1−2	hr 2
Positive	bottles	are	removed	as	soon	are	flagged	positive 3
Question	15:	What	is	the	average	time	of	communication	
of	the	Gram-stain	results	(calculated	starting	from	the	
time	a	BC	turned	positive	to	the	final	reporting	to	the	
clinician)?
 
>2	hr 0
1−2	hr	along	the	day	and	>2	hr	in	the	night 1
1−2	hr 2
<1	hr 3
Question	16:	Do	you	adopt	rapid	identification	methods	
and	rapid	antimicrobial	susceptibility	testing	directly	on	
positive	broth	culture?	If	so,	which	ones?
 
Not	valuable  
Question	17:	Does	your	laboratory	information	system	
record	and	manage	(for	statistical	analysis)	the	times	to	
positivity	for	each	bottle?	If	yes,	reports	the	average.
 
>50	hr 0
30−50	hr 1
15−30	hr 2
0−15	hr 3
Question	18:	What	is	your	BC	positive	rate?  
<1%	or	>19% 0
1%–3%	or	17%–19% 1
3%–5%	or	15%–17% 2
5%–15% 3
Question	19:	What	is	your	BC	contamination	rate?	Do	
you	produce	cumulative	reports	as	support?
 
>10% 0
4%–10% 1
3%–4% 2
≤2%–3% 3
TA B L E  A 1   (Continued)
